Regeneron Pharmaceuticals’ (REGN) Sector Perform Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reiterated their sector perform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report report published on Tuesday,Benzinga reports. Royal Bank Of Canada currently has a $737.00 price objective on the biopharmaceutical company’s stock.

A number of other research analysts have also recently commented on the company. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a research note on Tuesday, July 7th. Truist Financial lifted their price target on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. HSBC upped their price objective on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Finally, Morgan Stanley raised their price objective on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $809.50.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $734.81 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals has a one year low of $541.00 and a one year high of $859.34. The stock has a market cap of $75.66 billion, a PE ratio of 18.16, a P/E/G ratio of 1.49 and a beta of 0.16. The firm has a 50 day simple moving average of $786.71 and a two-hundred day simple moving average of $720.83.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $12.81 EPS. On average, analysts predict that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Zoghbi sold 800 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 3,946 shares of company stock worth $3,302,458 over the last three months. Company insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $5,682,636,000. State Street Corp grew its holdings in shares of Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after purchasing an additional 170,210 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Regeneron Pharmaceuticals by 4.4% in the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock worth $1,975,990,000 after buying an additional 106,861 shares during the period. Nuveen LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after buying an additional 835,240 shares during the period. Finally, Invesco Ltd. raised its holdings in Regeneron Pharmaceuticals by 7.2% during the 4th quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company’s stock valued at $1,228,127,000 after buying an additional 106,632 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Expanded Sanofi alliance provides substantial financial and strategic support. Regeneron will receive $1 billion upfront and could receive up to $7 billion in milestone payments as the companies add four next-generation, long-acting immunology antibodies—including REGN20423—to their collaboration. They will share development and commercialization costs and future profits. Regeneron and Sanofi Expand Global Alliance
• Positive Sentiment: Trevogrumab produced encouraging obesity-study results. In the Phase 2 COURAGE trial, trevogrumab prevented approximately 70% of the lean-mass loss associated with semaglutide in an MRI substudy, addressing a key concern with GLP-1 weight-loss treatment. The findings could support a combination approach and expand Regeneron’s obesity pipeline. Phase 2 COURAGE Trial
• Positive Sentiment: Analyst sentiment improved. Jefferies raised its price target to $930 and maintained a Buy rating, while Argus upgraded REGN to Buy with an $850 target, suggesting potential upside based on the company’s pipeline and earnings outlook.
• Neutral Sentiment: Ubamatamab showed promising but preliminary ovarian-cancer activity. At the highest dose, 11 heavily pretreated patients with low-grade serous ovarian cancer recorded a 73% objective response rate and median progression-free survival of 11 months. However, the small, early-stage dataset requires confirmation in larger studies. Ubamatamab ovarian cancer study
• Negative Sentiment: Investors initially reacted negatively to the ubamatamab data. The stock declined following coverage of the ovarian-cancer results, indicating that the market may have viewed the limited sample size, early development stage, or overall risk profile as insufficient to justify near-term gains. RBC’s Sector Perform rating also provides a more cautious counterpoint to the recent upgrades.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.